Australia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
108.61-1.82 (-1.65%)
At close: 04:00PM EDT
107.33 -1.28 (-1.18%)
Pre-market: 08:22AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close110.43
Open110.79
Bid107.40 x 1100
Ask107.52 x 1000
Day's range108.58 - 110.79
52-week range95.50 - 188.99
Volume212,001
Avg. volume677,447
Market cap26.042B
Beta (5Y monthly)0.18
PE ratio (TTM)5.81
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 June 2022
1y target estN/A
  • GlobeNewswire

    BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

    BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of vaccine candidatesData generated by this partnership will contribute to CEPI’s 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against future viral threats with pandemic potentialThe partnership is part of BioNTech’s strategy to

  • Business Wire

    Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

    NEW YORK & MAINZ, Germany, September 11, 2023--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. This season’s vaccine is indicated as a single

  • Business Wire

    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

    NEW YORK & MAINZ, Germany, August 30, 2023--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. The Committee has als